Olink Holding AB OLK announced that the UK Competition and Markets Authority (CMA) has unconditionally approved the tender offer by Orion Acquisition AB, a subsidiary of Thermo Fisher Scientific Inc. TMO. The offer price is set at $26 per share and includes all outstanding Common Shares and American Depositary Shares of Olink. Following this approval, Olink and Thermo Fisher anticipate completing the deal shortly after the offer's expiration on Jul 9, 2024. More on the Acquisition On Oct 17, 2023,Thermo Fisher announced its plans to acquire Olink. The deal, valued at approximately $3.1 billion or 26 per share, represented a 74% premium over Olink’s closing price of $14.98 on Oct 16, 2023. This acquisition enables Thermo Fisher to leverage Olink’s innovative proteomics solutions, driving growth and accelerating scientific advancements in life sciences. Upon completion, Olink will join Thermo Fisher’s Life Sciences Solutions segment, marking a significant milestone in the strategic expansion of Thermo Fisher’s proteomics capabilities. Strategic Significance Per Olink, CMA’s unconditional approval marks a pivotal step in the acquisition process, signaling regulatory confidence in the merger’s compliance with competition laws. This clearance paves the way for Thermo Fisher to expand its portfolio, enhancing its capabilities in the proteomics and genomics sectors through Olink's innovative technologies. The approval also provides certainty to shareholders and stakeholders, assuring them of a smooth and timely transition. Olink, post its merger, will be able to leverage Thermo Fisher’s deep life sciences expertise, global reach and proven operational excellence to progress in the prospering field of proteomics solutions. As far as Thermo Fisher is concerned, this acquisition is expected to bolster its market position and drive growth in life sciences, benefiting from Olink's cutting-edge proteomics solutions. Industry Prospects Per a report by MarketsandMarkets, the global proteomics market size was valued at $36.8 billion in 2023. It is anticipated to reach $72.9 billion in 2028 at a CAGR of 14.6% The field of proteomics has seen significant advancements, revolutionizing its capabilities and applications. These advancements include improved sensitivity and resolution, providing high-throughput and multiplexed analysis, facilitating data integration, enhancing sample preparation and fractionation techniques, enabling mass spectrometry-based imaging and providing advanced data analysis and informatics tools. Recent Developments This month, Olink’s establishment of Olink Certified Service Providers marked a significant step in accelerating scientific discovery and making advanced proteomics technology more accessible to researchers worldwide. This innovative ecosystem is set to drive forward biomarker research with unmatched precision and reliability. In the previous month, Carl Raimond, president of Olink, expressed excitement about the potential of the new panel to provide predictive insights into therapeutic responses and disease progression, moving closer to the realization of precision medicine. This addition to Olink’s portfolio of next-generation proteomics solutions enhances the company’s offerings from discovery to translational applications, supporting all stages of drug development and disease characterization. Price Performance Shares of Olink have increased 3.4% so far this year against the industry's 19.3% fall. The S&P 500 has witnessed a 17.5% rise in the same time frame. Zacks Investment Research Image Source: Zacks Investment Research Zacks Rank & Key Picks Currently, Olink carries a Zacks Rank #4 (Sell). Two better-ranked stocks in the broader medical space are DaVita Inc. DVA and Universal Health Services UHS. DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. DaVita’s shares have gained 43.4% compared with the industry’s 15.2% rise in the past year. Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.80%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%. Universal Health Services has gained 21.3% against the industry’s 20.4% decline in the past year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Universal Health Services, Inc. (UHS):Free Stock Analysis Report DaVita Inc. (DVA):Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO):Free Stock Analysis Report Olink Holding AB (publ) Sponsored ADR (OLK):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Olink's (OLK) Acquisition by Thermo Fisher Gets UK CMA Nod
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...